Skip to Content

Bazedoxifene / Conjugated Estrogens Dosage

Medically reviewed on January 15, 2018.

Applies to the following strengths: 20 mg-0.45 mg

Usual Adult Dose for Osteoporosis

Initial dose: Bazedoxifene-conjugated estrogens 20 mg-0.45 mg tablet orally daily
Duration of therapy: Bazedoxifene-conjugated estrogens should be for the shortest duration consistent with treatment goals and risks for the patient.

Approved indication: Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause and
Prevention of Postmenopausal Osteoporosis.

Usual Adult Dose for Postmenopausal Symptoms

Initial dose: Bazedoxifene-conjugated estrogens 20 mg-0.45 mg tablet orally daily
Duration of therapy: Bazedoxifene-conjugated estrogens should be for the shortest duration consistent with treatment goals and risks for the patient.

Approved indication: Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause and
Prevention of Postmenopausal Osteoporosis.

Renal Dose Adjustments

Not recommended

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNINGS:
-ENDOMETRIAL CANCER: There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. This drug has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
-CARDIOVASCULAR DISORDERS: The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (0.625 mg)­ alone, relative to placebo.
-PROBABLE DEMENTIA: The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older during 5.2 years of treatment with daily conjugated estrogens (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women.
-Women taking this drug should not take additional estrogens.
-Estrogen therapy should not be used for prevention of cardiovascular disease or dementia.
-In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens and other dosage forms of estrogens.
-Estrogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

This drug is not recommended for use in children.

Consult WARNINGS section for dosing related precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Take without regard to meals
-Swallow tablets whole
-If taking for prevention of postmenopausal osteoporosis supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate
-If a dose is missed, it should be taken as soon as remembered, but two doses should not be taken at the same time

Storage requirements:
-Tablets should not be removed from blisters
-After opening foil pouch, product must be used within 60 days

General: When prescribed for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be considered.

Monitoring: Thyroid function in women on thyroid replacement

Patient advice:
-Do not place in pill boxes or pill organizers
-Record date that the blister package is opened in the space provided on the package

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide